Fusion Pharmaceuticals Inc.
(NASDAQ GS: FUSN)
Rigrodsky Law, P.A. is investigating Fusion Pharmaceuticals Inc. (“Fusion”) regarding possible breaches of fiduciary duties and other violations of law related to Fusion’s agreement to be acquired by AstraZeneca. Under the terms of the agreement, Fusion shareholders will receive $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone.